Advanced chronic kidney disease with life-threatening hypokalemia due to undiagnosed Gitelman syndrome

We report a case of a 58-year-old woman presenting with symptoms of oliguria, fatigue, anorexia, constipation, hypovolemic signs, and laboratory tests showing severe hypokalemia (1.7 mEq/L), hyponatremia (120 mEq/L), high serum creatinine (SCr, 6.46 mg/dL) and urea (352 mg/dL). The patient had previously been diagnosed with chronic kidney disease (CKD), with SCr up to 2.58 mg/dL 1 year prior, and had in all her previous laboratory tests shown hypokalemia, which was treated with conservative measures and eplerenone despite low-normal blood pressure and normal heart function. A set of coordinated measures were applied to restore the potassium deficit, revert hypovolemic hyponatremia, and support renal function (including 4 dialysis sessions). In addition, a careful diagnostic approach revealed inappropriately high urine sodium and potassium losses, hypocalciuria, and hyperreninemic hyperaldosteronism leading to the diagnosis of Gitelman syndrome and hypokalemia-associated chronic tubulointerstitial nephropathy. Importantly, compliance with a simple set of instructions on high potassium and liberal sodium diet enabled the patient not only to remain euvolemic, free of symptoms, and with normal electrolytes, but also to recover a significant part of renal function and stabilize at an earlier CKD stage. Gitelman syndrome is a rare disorder that can be easily diagnosed and treated following simple measures; its early diagnosis is necessary to avoid life-threatening complications.

[1]  Q. Wan,et al.  Diagnostic value of parameters from a spot urine sample for renal potassium loss in hypokalemia. , 2020, Clinica chimica acta; international journal of clinical chemistry.

[2]  D. Goldfarb,et al.  The Association of Mesalamine With Kidney Disease. , 2020, Advances in chronic kidney disease.

[3]  F. Jaisser,et al.  Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis. , 2019, Kidney international.

[4]  D. Clegg,et al.  The Use of Selected Urine Chemistries in the Diagnosis of Kidney Disorders. , 2019, Clinical journal of the American Society of Nephrology : CJASN.

[5]  K. Nakanishi,et al.  Clinical and Genetic Characteristics in Patients With Gitelman Syndrome , 2018, Kidney international reports.

[6]  D. Armanini,et al.  Proinflammatory/profibrotic effects of aldosterone in Gitelman’s syndrome, a human model opposite to hypertension , 2018, Journal of Endocrinological Investigation.

[7]  M. Tonelli,et al.  National Kidney Foundation's Primer on Kidney Diseases , 2017 .

[8]  A. Subramanya,et al.  Distal convoluted tubule. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[9]  R. Schrier,et al.  Glomerular hyperfiltration: definitions, mechanisms and clinical implications , 2012, Nature Reviews Nephrology.

[10]  P. Houillier,et al.  Does hypokalaemia cause nephropathy? An observational study of renal function in patients with Bartter or Gitelman syndrome. , 2011, QJM : monthly journal of the Association of Physicians.

[11]  D. Kahila,et al.  Spectrum of mutations in Gitelman syndrome. , 2011, Journal of the American Society of Nephrology : JASN.

[12]  K. Yamauchi,et al.  Effect of lactulose on calcium and magnesium absorption: a study using stable isotopes in adult men. , 2007, Journal of nutritional science and vitaminology.

[13]  M. Hayashi [Bartter syndrome and Gitelman syndrome]. , 2006, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.

[14]  T. Horio,et al.  Endothelin a receptor blockade and endothelin B receptor blockade improve hypokalemic nephropathy by different mechanisms. , 2003, Journal of the American Society of Nephrology : JASN.

[15]  Y. G. Kim,et al.  Hypokalemia induces renal injury and alterations in vasoactive mediators that favor salt sensitivity. , 2001, American journal of physiology. Renal physiology.

[16]  L. Bonfante,et al.  Chronic renal failure, end-stage renal disease, and peritoneal dialysis in Gitelman's syndrome. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  B. Brenner,et al.  The hyperfiltration theory: a paradigm shift in nephrology. , 1996, Kidney international.

[18]  T. Hostetter,et al.  Hypokalemic nephropathy in the rat. Role of ammonia in chronic tubular injury. , 1987, The Journal of clinical investigation.

[19]  D. Bolignano,et al.  Gitelman Syndrome: Consensus and Guidance From a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference , 2017 .

[20]  T. Filippatos,et al.  Gitelman syndrome: an analysis of the underlying pathophysiologic mechanisms of acid–base and electrolyte abnormalities , 2017, International Urology and Nephrology.

[21]  M. Ayyub,et al.  Gitelman Syndrome. , 2017, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.

[22]  J. Navarro-González,et al.  Reviews: Clinical Implications of Disordered Magnesium Homeostasis in Chronic Renal Failure and Dialysis , 2009, Seminars in dialysis.

[23]  Takahiko Nakagawa,et al.  Hypokalemic nephropathy is associated with impaired angiogenesis. , 2008, Journal of the American Society of Nephrology : JASN.

[24]  Salim Lim Approach to hypokalemia. , 2007, Acta medica Indonesiana.

[25]  Y. Hirata,et al.  [Endothelin receptor]. , 1997, Nihon rinsho. Japanese journal of clinical medicine.

[26]  A. W. Anderson,et al.  HYPOKALEMIC NEPHROPATHY. , 1965, The Journal of the Florida Medical Association. Florida Medical Association.